2024 年第 9 期 第 0 卷

替奈普酶在急性下肢深静脉血栓形成置管溶栓术辅助治疗中的临床效果观察

Clinical effect observation of teneplase in the adjuvant treatment of acute lower extremity deep vein thrombosis with catheter-directed thrombolysis

作者：田中袁福康田志龙

英文作者：Tian Zhong Yuan Fukang Tian Zhilong

单位：徐州医科大学徐州临床学院徐州市中心医院血管外科，徐州221009

英文单位：Department of Vascular Surgery the Affiliated Xuzhou Clinical College of Xuzhou Medical University Xuzhou Central Hospital Xuzhou 221009 China

关键词：急性下肢深静脉血栓形成；置管溶栓术；替奈普酶；尿激酶；临床效果

英文关键词：Acutelowerextremitydeepveinthrombosis;Catheter-directedthrombolysis;Teneplase;Urokinase;Clinicaleffect

• 摘要：

• 目的 观察替奈普酶在急性下肢深静脉血栓形成（DVT）置管溶栓术（CDT）辅助治疗中的临床效果。方法 收集徐州市中心医院血管外科2022年1月至2023年6月收治的104例急性下肢DVT患者的临床资料行回顾性分析。基于不同的疗法将患者归为联合组（50例）和尿激酶组（54例）。评价2组患者术后静脉通畅评分、静脉通畅率、患肢消肿率、血栓清除分级、尿激酶用量、溶栓时间、住院时间及并发症等指标。结果 联合组术后静脉通畅评分小于尿激酶组，术后静脉通畅率、患肢消肿率均大于尿激酶组［（1.6±1.0）分比（2.3±1.1）分、（79±13）%比（68±15）%、（73±12）%比（66±8）%］，差异均有统计学意义（均P<0.05）。2组血栓清除分级差异无统计学意义（P>0.05）。联合组患者尿激酶用量、溶栓时间、住院时间少于/短于尿激酶组，差异均有统计学意义（均P<0.05）。2组术后并发症发生率差异无统计学意义（P>0.05）。结论 与单纯使用尿激酶相比，替奈普酶辅助尿激酶进行CDT治疗急性下肢DVT，可减少尿激酶用量、缩短溶栓时间和住院时间，近期溶栓效果肯定且操作简便。

• Objective To observe the clinical effect of teneplase in the adjuvant treatment of acute lower extremity deep vein thrombosis (DVT) with catheter-directed thrombolysis (CDT). Methods A retrospective analysis was conducted on the clinical data of 104 patients with acute lower extremity DVT admitted to the Department of Vascular Surgery, Xuzhou Central Hospital from January 2022 to June 2023. Patients were classified into the combination group (50 cases) and the urokinase group (54 cases) based on different therapies. Postoperative venous patency score, venous patency rate, limb swelling reduction rate, thrombus clearance grade, urokinase dosage, thrombolysis time, hospital stay, and complications in two groups of patients were compared. Results The postoperative venous patency score of the combined group was lower than that of the urokinase group, and the postoperative venous patency rate and limb swelling reduction rate were both higher than those of the urokinase group［(1.6±1.0) vs (2.3±1.1), (79±13)% vs (68±15)%, (73±12)% vs (66±8)%］, with statistically significant differences (all P<0.05). There was no statistically significant difference in thrombus clearance grading between the two groups (P>0.05). The dosage of urokinase, thrombolysis time, and hospital stay of patients in the combination group were less/shorter than those in the urokinase group, and the differences were statistically significant (all P<0.05). There was no statistically significant difference in the incidence of postoperative in two groups (P>0.05). Conclusions Compared with the use of urokinase alone, the use of teneplase assisted urokinase for CDT treatment of acute lower extremity DVT can reduce the amount of urokinase dosage, and shorten thrombolysis time and hospital stay. The recent thrombolysis effect is certain and the operation is simple.